Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Testosterone Enanthate | Testosterone Propionate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement. | Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection. |
| Timing | Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate. | Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation. |
| Cycle Duration | Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation. | Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden. |
| Evidence Level | strong_human | strong_human |
Testosterone enanthate is a long-acting esterified testosterone prodrug with a heptanoic acid ester at the 17-beta hydroxyl group, extending its half-life to approximately 4.5-5 days. Upon hydrolysis by tissue esterases, free testosterone activates nuclear androgen receptors, upregulating anabolic gene transcription including myostatin suppression and IGF-1 induction. It also modulates the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH and LH secretion.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement.
Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate.
Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation.
Testosterone propionate is a short-acting esterified testosterone with a propionic acid ester, resulting in a half-life of approximately 0.8-1.5 days. Rapid hydrolysis by serum esterases produces a sharp testosterone spike followed by quick clearance. It activates the same androgen receptor-mediated genomic and non-genomic pathways as longer esters, but the pharmacokinetic profile demands frequent dosing. The short duration makes it useful for rapid onset situations and fine-tuned dose titration.
Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection.
Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation.
Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →